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Abstract
Background: Clinical trial (CT) participation may confer access to new, potentially active agents before their general
availability. This study aimed to investigate the potential survival benefit of participation in investigational CTs of
novel hormonal, chemotherapeutic, and radiopharmaceutical agents in patients with castration-resistant prostate
cancer (CRPC).
Methods: This multi-center, retrospective analysis included 299 consecutive patients with newly diagnosed, non-
metastatic or metastatic CRPC between September 2009 and March 2017. Of these, 65 (21.7%) patients participated
in CTs pertaining to systemic treatment targeting CRPC and 234 (78.3%) patients received pre-established, standard
systemic treatment outside of a CT setting. The survival advantage of CT participation regarding cancer-specific
survival (CSS) was investigated.
Results: An Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2 at CRPC diagnosis was found
in a lower proportion CT participants than in non-participants (4.6% vs. 14.9%; p = 0.033). During the median follow-
up period of 16.0 months, CT participants exhibited significantly higher 2-year CSS survival rates (61.3% vs. 42.4%; p
= 0.003) than did non-participants. Multivariate analysis identified prostate-specific antigen and alkaline phosphatase
levels at CRPC onset, Gleason score≥ 8, ECOG PS ≥2, less number of docetaxel cycles administered, and non-participation
in CTs as independent predictors for a lower risk of CSS.
Conclusions: Patients diagnosed with CRPC who participated in CTs exhibited longer CSS durations than non-
participants who received pre-established, standard systemic therapy outside of a CT setting. Our findings imply
that CT participation is associated with CSS, and that CT participation should be offered to patients with CRPC
whenever indicated.
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Background
In line with advances in clinical research, the treatment
of castration-resistant prostate cancer (CRPC) has
evolved, with the development of novel hormonal, che-
motherapeutic, radiopharmaceutical, and immunothera-
peutic drugs [1]. Approval of these agents was based on
the results of large, well-designed, randomized phase III
clinical trials (CTs) that demonstrated improvement in
overall survival [2–5]. However, there is still an unmet
need to provide individualized therapeutic options, and
the requirement for novel agents based on various path-
ways and targets continues to exist.
Participation in CTs may confer access to new, poten-
tially active therapeutic agents before their general
availability. Moreover, these investigational agents may
be the best current treatment option for a subset of pa-
tients. Currently, there is ongoing research into and de-
velopment of novel agents targeting CRPC, including
androgen receptor inhibitors, cytochrome P450 17
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inhibitors, targeted agents, vaccines, and poly-ADT-
ribose polymerase inhibitors [6–8]. A randomized CT is
a crucial step in the development of new cancer treat-
ments, and as with previously approved drugs, the effi-
cacy of these novel agents will need to be confirmed by
adequate statistical power through CTs before their ap-
plication in clinical practice.
Physicians offer enrollment in CTs assuming that sur-
vival benefits may be obtained from participation.
Participating in CTs may also provide patients with hope
of an individualized survival benefit conferred by the use
of potentially effective agents that would not have been
received outside the trial setting. Indeed, several studies
have shown entry into cancer CTs to be associated with
increased survival rates [9, 10]. On the other hand, con-
cerns around the uncertainty associated with the experi-
mental nature of CTs, the randomization process,
unknown potential toxicity, and the time delay until
proven standard therapy is available are documented
barriers to enrollment [11–13].
With advances in understanding the mechanisms
underlying castration-resistance and disease progression,
CTs of investigational drugs targeted at CRPC will con-
tinue. Ideally, CTs should be offered as the best treat-
ment option for patients based on evidence that
participation may improve survival outcomes. Indeed,
several investigations have reported a favorable overall
trend with CT entry [14–16]. However, data on whether
CTs targeted at CRPC may confer benefit in regard to
survival are limited. The objective of this retrospective
study was to determine the independent cancer-specific
survival (CSS) advantage of participation in investiga-
tional CTs of hormonal, chemotherapeutic, and radio-
pharmaceutical agents targeted at CRPC.
Methods
Study population
A multicenter, retrospective analysis was performed
using a prospectively collected database of 331 consecu-
tive patients who were diagnosed with non-metastatic or
metastatic CRPC between September 2009 and March
2017. Prostate cancer staging was based on the 7th
American Joint Committee on Cancer TNM system,
with the definition of bone metastasis based on either
demonstrable metastatic deposits on imaging studies
(bone scan, computed tomography, magnetic resonance
imaging, or positron emission tomography) or by patho-
logical confirmation. Patients were excluded from the
analysis if they met any of the following criteria: incom-
plete clinical data (n = 14), lost to follow-up (n = 10), or
unknown cause of death (n = 8).
Once diagnosed with CRPC, patients’ eligibility for
participation in available CTs pertaining to novel hormo-
nal, chemotherapeutic, and radiopharmaceutical
investigational agents was assessed. The eligibility cri-
teria for 18 CTs are listed in Table 1. Patients who did
not meet the eligibility criteria or who refused to partici-
pate in CTs received systemic treatment according to
standard U.S. Food and Drug Administration-approved
dose and schedule. The choice and sequencing of stand-
ard agents were based on physician discretion and
patient preference. Each agent was continued until the
occurrence of radiographic disease progression, intoler-
able side-effects, patient refusal, or death. Serum
prostate-specific antigen (PSA) measurements were per-
formed every 1 to 3 months, and computed tomography
and bone scans were performed every 2 to 4 months.
This study was approved by the Yonsei University
Health System Institutional Review Board after a review
of the study protocol (2017–0186-001).
Data collection and definitions
The patients’ clinical and pathological characteristics at
CRPC diagnosis were retrieved from the institutional
electronic medical record database. The obtained data
included patient age; body mass index; serum PSA level
at CRPC diagnosis; Gleason score; AJCC stage; previous
local treatments received; Charlson Comorbidity Index
(CCI); Eastern Cooperative Oncology Group perform-
ance score (ECOG PS); the site of metastasis; duration
of docetaxel, abiraterone, enzalutamide, cabazitaxel, and
radium-223 dichloride administration; docetaxel to an-
drogen receptor axis-targeted agent sequencing; and la-
boratory values including peripheral blood hemoglobin,
albumin, and alkaline phosphatase levels, and white
blood cell counts.
CRPC was defined and evaluated according to the criteria
of the Prostate Cancer Clinical Trials Working Group 2
[17]. The CSS interval was defined as the interval from the
date of initial CRPC diagnosis to the date of death from
prostate cancer. Patient survival and causes of death were
investigated based on the National Cancer Registry Data-
base or institutional electronic medical records.
Statistical analysis
Clinicopathologic data were compared between CT par-
ticipants and non-participants using descriptive statistics.
Fisher’s exact test and the chi-squared test were used to
compare categorical variables. The Mann-Whitney U-test
was used to compare continuous variables across dichot-
omous categories. Kaplan-Meier curves were used to esti-
mate CSS according to CT participation, with p-values
computed using the log-rank test.
Univariate and multivariate Cox proportional hazards
regression analyses were used to adjust for potential
confounders in predicting CSS. All covariates with sig-
nificant p-values in the univariate model were included
in the multivariate model. Statistical analyses were
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Table 1 Clinical trial protocols included in this analysis
NCT identifier Trial title Phase Reference
NCT01946204 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of
ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Phase
III
Apalutamide versus placebo
NCT00744497 A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined
With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant
Prostate Cancer
Phase
III
Dasatinib, docetaxel, prednisone versus
placebo, docetaxel, prednisone
NCT02057666 A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod
In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
Phase
III
Tasquinimod versus placebo
NCT01234311 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod
in Men With Metastatic Castrate Resistant Prostate Cancer
Phase
III
Tasquinimod versus placebo
NCT01188187 A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone
to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With
Metastatic Castrate Resistant Prostate Cancer
Phase
III
Custirsen, docetaxel, prednisone versus
docetaxel, prednisone
NCT02023697 A Three Arm Randomized, Open-label Phase II Study of Radium-223 Dichloride
50 kBq/kg (55 kBq/kg After Implementation of NIST Update) Versus 80 kBq/kg
(88 kBq/kg After Implementation of NIST Update), and Versus 50 kBq/kg
(55 kBq/kg After Implementation of NIST Update) in an Extended Dosing Schedule
in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone
Phase
II
Radium-223 dichloride standard versus high
versus extended standard doses
NCT01212991 Prevail: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled
Efficacy And Safety Study Of Oral Mdv3100 In Chemotherapy-naïve Patients With
Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation
Therapy
Phase
III
Enzalutamide versus placebo
NCT01685983 A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and
Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed
Androgen Deprivation and Docetaxel-Based Chemotherapy
Phase
II
Abiraterone versus prednisolone
NCT02003924 Prosper: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled,
Efficacy And Safety Study Of Enzalutamide In Patients With Nonmetastatic
Castration-resistant Prostate Cancer
Phase
III
Enzalutamide versus placebo
NCT01977651 A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate
the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate
Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk
of Seizure
Phase
IV
Enzalutamide
NCT02987543 A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety
of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men
With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior
Treatment With a New Hormonal Agent and Have Homologous Recombination
Repair Gene Mutations (PROfound)
Phase
III
Olaparib versus enzalutamide or abiraterone
acetate
NCT01188187 A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone
to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With
Metastatic Castrate Resistant Prostate Cancer
Phase
III
Custirsen, docetaxel, prednisone versus
docetaxel, prednisone
NCT02200614 A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy
and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic
Castration-resistant Prostate Cancer
Phase
III
BAY1841788 (ODM-201) versus placebo
NCT02257736 A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-
56021927 in Combination With Abiraterone Acetate and Prednisone Versus
Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase
III
Apalutamide, abiraterone acetate, prednisone
versus abiraterone acetate, prednisone
NCT00626548 A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the
Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan)
10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
Phase
III
Zibotentan versus placebo
NCT00554229 A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A
Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant
Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly
Symptomatic
Phase
III
Zibotentan versus placebo
NCT02677896 A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy
and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT)
Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate
Cancer (mHSPC)
Phase
III
Enzalutamide, androgen deprivation therapy
versus placebo, androgen deprivation therapy
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performed using IBM SPSS software (version 23; IBM
Corp., Armonk, NY, USA). All tests were two-tailed,
with statistical significance set at a p-value of < 0.05.
Results
Baseline characteristics
The baseline clinical and pathological features of the
overall population and of the subgroups stratified by CT
participation are presented in Table 2. Of the 299 pa-
tients, 65 (21.7%) participated in CTs pertaining to sys-
temic treatment target at CRPC while 234 (78.3%)
received pre-established, standard systemic treatment
outside of a CT setting. A lower proportion of CT par-
ticipants had ECOG PS ≥2 at CRPC diagnosis than did
non-participants (4.6% vs. 14.9%; p = 0.033), while PSA
levels at CRPC diagnosis were lower in CT participants
compared to non-participants (25.8 ng/mL vs. 88.4 ng/
mL; p = 0.005). Distributions of potential survival prog-
nosticators of CRPC, namely, age, body mass index,
TNM stages, Gleason score, metastatic sites, and CCI
were comparable between the two groups.
The treatments administered for CRPC are described
in Table 3. CT participants received significantly more
cycles of docetaxel than did non-participants managed
outside the CT setting. Because of Korea’s National
Health Insurance policy of providing reimbursement for
enzalutamide used for post-chemotherapy patients with
CRPC, enzalutamide was predominantly used in the
post-docetaxel setting. There were no differences be-
tween the two groups in terms of the proportions of
other systemic treatments used.
Survival outcome according to clinical trial participation
Survival results as of September 2017 were used in this
analysis and are presented in Table 4 and Fig. 1. During
the median follow-up period of 16.0 months, the median
CSS interval was 13.0 months. Overall, 187 (66.3%)
cancer-specific deaths were noted, which translated to a
2-year CSS rate of 46.8%. CT participants exhibited sig-
nificantly higher 2-year CSS rates than non-participants
(61.3% vs. 42.4%; p = 0.003).
Predictors of cancer-specific survival
Predictors of CSS are presented in Table 5. Univariate
Cox-regression analyses demonstrated that patient age,
PSA level at CRPC diagnosis, albumin and alkaline
phosphatase levels, biopsy Gleason score ≥ 8, ECOG PS
≥2, less number of docetaxel cycles administered, and
non-participation in CTs were associated with lower risk
of CSS. Multivariate analysis revealed that PSA at CRPC
diagnosis, alkaline phosphatase level, biopsy Gleason
score ≥ 8, ECOG PS ≥2, less number of docetaxel cycles
administered, and non-participation in CTs independ-
ently predicted lower risk of CSS.
Discussion
Systemic treatment for CRPC has rapidly evolved.
Identifying patients for judicious application of optimal
treatment strategies is imperative in the current era of
multidisciplinary treatment options. However, the selec-
tion of agents is often limited by the availability of novel
agents and reimbursement issues. In this regard, partici-
pation in CTs may provide a breakthrough opportunity
for access to innovative therapeutic approaches in
addition to third party payer coverage. Participation in
CTs is based on the patient’s notion that a survival bene-
fit can be achieved. Our study demonstrated that partici-
pation in CTs pertaining to CRPC agents, compared
with non-participation, may improve CSS regardless of
metastatic status.
The biological mechanisms underlying improved CSS
observed with CT participation in our study is unclear;
however, several reasons have been proposed. First, an
experimental treatment effect may have existed, in which
CT participants received better treatment in early-phase
CTs than they would have received with standard ther-
apies [9]. This effect may potentially have affected our
results in that systemic agents that have been identified
to prolong survival—namely, abiraterone, enzalutamide,
docetaxel, and radium-223 dichloride—were included in
either the experimental or control arms in 66% of CTs
included in our analysis. Furthermore, potential selection
bias may arise from the 32 patients who were excluded
from final analysis, if these patients had been allocated
to receive novel agents without proven survival benefit.
However, among the four excluded patients in the CT
participation group, three patients had received abirater-
one or docetaxel while one patient was blinded to arm
allocation, precluding any alteration in our study results.
Second, a participation effect may have existed, in which
aspects of CT participation other than exposure to investi-
gational therapy may have improved outcomes [14]. Spe-
cifically, the participation effect comprises the following:
1) a protocol effect regarding the way the treatments are
delivered; 2) a care effect including incidental aspects of
care; 3) the Hawthorne effect, which is initiated by
Table 1 Clinical trial protocols included in this analysis (Continued)
NCT identifier Trial title Phase Reference
NCT01217697 An Open Label Study of Abiraterone Acetate in Subjects With Metastatic
Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based
Chemotherapy
EAP Abiraterone acetate versus prednisone
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changes in physician or patient behavior in regard to the
perception that they are under observation; and 4) the pla-
cebo effect, which mediates the psychological behavior of
the participant based on the awareness that they are bene-
ficiaries of therapeutic advances [14, 16].
Third, the improved survival outcomes observed with
CT participation in our study may have resulted from
inherent differences in baseline patient and tumor fea-
tures. In our study, the performance status, as well as
PSA and albumin levels of patients who participated in
CTs were more favorable than those of non-participants;
this might have affected the results. However, the pro-
portions of potential survival confounders including age,
tumor stage and grade, metastatic burden, and
Table 2 Clinicopathologic characteristics of castration-resistant prostate cancer patients, stratified by clinical trial participation
Overall
(n = 299)
Clinical trial
Participants
(n = 65)
Non-participants
(n = 234)
p
Age 66.5 (61.0–71.8) 65.0 (62.0–71.0) 67.0 (61.0–72.0) 0.384
Body mass index 23.1 (20.9–24.7) 22.9 (21.3–24.7) 23.4 (21.2–25.1) 0.345
Laboratory valuesa
PSA (ng/mL) 69.2 (15.0–182.0) 25.8 (9.6–73.6) 88.4 (18.0–247.3) 0.005
Hemoglobin (g/dL) 12.0 (10.7–13.0) 12.4 (11.7–13.3) 11.9 (10.4–12.9) 0.514
Albumin (U/L) 4.0 (3.7–4.4) 4.3 (4.0–4.5) 4.0 (3.7–4.3) 0.001
ALP (U/L) 109.0 (70.0–209.0) 88.0 (67.0–133.5) 118 (71.0–221.5) 0.070
WBC count (× 109/L) 5.8 (4.8–7.3) 5.8 (4.7–7.3) 5.8 (4.9–7.3) 0.919
T stage 0.764
≤ T2 187 (62.5%) 42 (64.7%) 145 (61.9%)
≥ T3 112 (37.5%) 23 (35.3%) 89 (38.1%)
N stage 0.491
N0 127 (42.5%) 30 (46.2%) 97 (41.5%)
N1 172 (57.5%) 35 (53.8%) 137 (58.5%)
M stage 1.000
M0 73 (24.4%) 15 (23.1%) 58 (24.8%)
M1 226 (75.6%) 50 (76.9%) 176 (75.2%)
Metastatic site
Bone 166 (55.5%) 37 (57.0%) 129 (55.1%) 0.856
Visceral 8 (2.7%) 8 (12.3%) 0 (0.0%) 0.215
Lymph node 142 (47.5%) 26 (40.0%) 116 (49.6%) 0.116
Gleason score 0.267
≤ 7 156 (52.2%) 30 (46.2%) 126 (53.8%)
≥ 8 143 (47.8%) 35 (53.8%) 108 (46.2%)
CCI 0.780
≤ 1 142 (%) 32 (49.2%) 110 (47.0%)
≥ 2 157 (%) 33 (50.8%) 124 (53.0%)
ECOG PS 0.033
≤ 1 261 (87.3%) 62 (95.4%) 199 (85.1%)
≥ 2 38 (12.7%) 3 (4.6%) 35 (14.9%)
Primary treatmentb
Prostatectomy 149 (49.8%) 47 (72.3%) 102 (43.6%) < 0.001
Radiation therapy 33 (11.0%) 10 (15.4%) 23 (9.8%) 0.261
Data are presented as the median (interquartile range) or number (%)
aAt diagnosis of castration-resistant prostate cancer
bNumber of primary treatment does not sum to 299 patients due to the existence of men who did not receive any local treatment with curative intent
Abbreviations: ALP alkaline phosphatase, CCI Charlson Comorbidity Index, ECOG PS Eastern Cooperative Oncology Group performance status, PSA prostate-specific
antigen, WBC white blood cell
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comorbidities were comparable between the groups. To
overcome the challenge in separating possible true ef-
fects from false effects of the discrepancy in baseline pa-
tient and tumor features, statistical adjustments were
made for a comprehensive set of confounders of survival
among patients with CRPC, to confirm that CT partici-
pation itself was an independent prognosticator. Another
selection bias arises from the effect of protocol eligibility
criteria [12]. Most CTs included in our study strictly
prohibited enrollment of patients with advanced disease,
such as those with brain metastasis, an adverse prognos-
tic factor for several cancers [18–20]. However, the two
study groups had comparable proportions of metastatic
location and burden, corroborating our hypothesis.
Fourth, a bias in data collection with regard to survival
may have affected outcomes; survival follow-up could be
more completely censored in CT participants than in
non-participants. Moreover, patients in the advanced
stages of the disease who participated in CTs could have
been inherently more adherent to treatment follow-up
schedules, whereas non-participants might opted for
supportive care even if anti-cancer treatment may have
prolonged survival [16, 21].
The present study revealed that CT participants received
more docetaxel cycles than non- participants. Docetaxel re-
mains the standard treatment for metastatic CRPC and has
been the mainstay for CTs of sequential strategies since its
approval in 2004 [22]. The improved survival in CT partici-
pants may be attributed to better chemotherapy efficacy
and subsequent prolonged duration of docetaxel adminis-
tration, as shown in multivariate analysis. Our study also
demonstrated that Gleason score, and PSA and alkaline
phosphatase levels at CRPC diagnosis are independent pre-
dictors of CSS. These findings compare favorably to those
of previous retrospective studies that investigated prognos-
ticators for survival in patients with metastatic CRPC,
which implies that our cohort ably represented the whole
population of the disease status and that our conclusions
are generalizable [23, 24].
With our use of retrospective data, it is difficult to de-
termine which of the abovementioned effects contrib-
uted to the survival benefit associated with CT
participation. Indeed, a randomized controlled trial in
which patients are randomized to be offered CT partici-
pation would be warranted to ensure baseline compar-
ability and to investigate potential confounders.
However, if at least one of the abovementioned effects
may have truly affected improved CSS outcome in our
CT participants, it would provide evidence to offer CT
participation whenever indicated to patients with CRPC
for its inherent survival advantage.
The strengths of the current study include the incorp-
oration of comprehensive survival prognosticators of
CRPC, including patient and tumor characteristics, co-
morbidities, performance status, laboratory values, and
treatment information that were available for all pa-
tients. Furthermore, CT participants included in our
study received novel hormonal, chemotherapeutic, and
radiopharmaceutical therapeutic agents approved in the
last 8 years, which suggests that our results are applic-
able in this contemporary era of multidisciplinary treat-
ment strategies. At the same time, several limitations are
worth mentioning. First, selection bias may have existed
Table 3 Treatments administered for castration-resistant pros-
tate cancer
Overall
(n = 299)
Clinical trial
Participants
(n = 65)
Non-participants
(n = 234)
p
Docetaxel
N 242
(80.9%)
41 (63.1%) 201 (85.9%) 0.001
No. cycles 4.0
(2.0–9.0)
7.0
(4.0–12.5)
4.0 (2.0–9.0) 0.003
ARAT agent use
Pre-chemotherapy 0.502
Abiraterone 10 (3.3%) 2 (3.1%) 8 (3.4%)
Enzalutamide 15 (5.0%) 4 (6.2%) 11 (4.7%)
Post-chemotherapy < 0.001
Abiraterone 23 (7.7%) 13 (20.0%) 10 (4.3%)
Enzalutamide 108
(36.1%)
9 (13.8%) 99 (42.3%)
Cabazitaxel 1 (0.3%) 0 (0.0%) 1 (0.4%) 1.000
Radium-223 5 (1.7%) 3 (4.6%) 2 (0.9%) 0.070
Abbreviations: ARAT androgen receptor axis-targeted
Table 4 Survival outcomes of patients with castration-resistant prostate cancer, stratified by clinical trial participation
Overall
(n = 299)
Clinical trial
Participants
(n = 65)
Non-participants
(n = 234)
p
No. cancer-specific deaths 187 (62.5%) 44 (67.7%) 143 (61.1%) 0.364
2-year cancer-specific survival 46.8% 61.3% 42.4% 0.003
CRPC to death (months) 13.0 (6.0–24.3) 23.5 (13.3–30.5) 11.0 (5.0–19.3) < 0.001
Total follow-up (months) 16.0 (7.2–26.0) 26.0 (16.0–39.8) 13.5 (6.0–24.0) < 0.001
Data are presented as number (%) or median (interquartile range)
Abbreviations: CRPC castration-resistant prostate cancer
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due to the retrospective nature of the study. This study
was a non-randomized study; therefore, there was a lack
of a standard therapeutic approach in which physician
and patient preferences existed regarding the implemen-
tation of a CT. Moreover, a discrepancy existed in treat-
ment protocols used in various CTs, such as the
frequency of imaging and laboratory testing, and be-
tween each physician who treated patients with standard
care. Second, the existence of unaccounted imbalances
in baseline patient and tumor characteristics cannot be
overlooked. However, these potential baseline discrepan-
cies which may have affected our outcomes were
accounted for, and our results were derived from multi-
variate Cox-regression analyses. Lastly, we did not ac-
count for the data of patients who participated in CTs
but later declined to continue and opted for best sup-
portive care, which may have affected survival outcomes.
The abstract of this article was presented at the 33rd
Annual EAU Congress [25].
Conclusions
This observational study provides novel findings that the
CSS outcomes of patients diagnosed with CRPC who
Fig. 1 Cancer-specific survival of patients with castration-resistant
prostate cancer, stratified by clinical trial participation versus non-
participation
Table 5 Predictors of cancer-specific mortality in patients with castration-resistant prostate cancer
Univariate Multivariate
HR (95% CI) P HR (95% CI) p
Age 1.038 (1.016–1.061) 0.001 1.020 (0.998–1.042) 0.069
Body mass index 0.968 (0.901–1.041) 0.382
PSAa 1.001 (1.000-1.001) < 0.001 1.001 (1.000–1.001) 0.018
Hemoglobina 1.001 (0.999-1.002) 0.306
Albumina 0.408 (0.301-0.553) < 0.001
Alkaline phosphatasea 1.001 (1.000–1.001) < 0.001 1.001 (1.001–1.002) < 0.001
T stage (≥T3 vs. ≤T2) 0.865 (0.524–1.430) 0.271
N stage (1 vs. 0) 1.251 (0.922–1.697) 0.152
M stage (1 vs. 0) 1.528 (0.983–2.376) 0.062
Gleason score (≥8 vs. ≤7) 1.957 (1.441–2.658) < 0.001 2.004 (1.452–2.767) < 0.001
CCI ≥4 1.197 (0.811–1.765) 0.365
ECOG ≥2 1.802 (1.216–2.670) 0.003 1.304 (1.164–2.158) 0.035
Docetaxel cycles 0.926 (0.900–0.953) 0.026 0.943 (0.915–0.972) 0.011
Primary treatment
Prostatectomy 1 (reference)
Radiation therapy 0.778 (0.580–1.141) 0.584
ARAT agent sequencing
Pre-chemotherapy 1 (reference)
Post-chemotherapy 0.865 (0.524–1.430) 0.572
Radium-223 administration 0.803 (0.255–2.527) 0.707
Clinical trial participation 0.593 (0.417–0.843) 0.004 0.585 (0.429–0.797) 0.038
aLaboratory values at diagnosis of castration-resistant prostate cancer
Abbreviations: ARAT androgen receptor axis-targeted, CI confidence interval, CCI Charlson Comorbidity Index, ECOG PS Eastern Cooperative Oncology Group performance
status, HR hazard ratio, PSA prostate-specific antigen
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participated in CTs were better than those of non-
participants who received pre-established, standard sys-
temic therapy outside of a CT setting. Our findings
imply that CT participation is associated with CSS, and
that CT participation should be offered to patients with
CRPC whenever indicated.
Abbreviations
CCI: Charlson Comorbidity Index; CRPC: Castration-resistant prostate cancer;
CSS: Cancer-specific survival; CT: Clinical trial; ECOG PS: Eastern Cooperative
Oncology Group performance score; PSA: Prostate-specific antigen
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